We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Stealth

News List

Stealth BioTherapeutics Joins the Rare Disease Company Coalition firstwordpharma
July 08, 2021
Stealth today announced that it has joined the Rare Disease Company Coalition, an alliance of life science companies committed to discovering, developing, and delivering rare disease treatments for the patients they collectively serve.
Elamipretide Study Does Not Meet Primary Endpoint americanpharmaceuticalreview
December 23, 2019
Stealth BioTherapeutics announced top-line data from the Phase 3 MMPOWER-3 trial evaluating elamipretide for treatment of patients with primary mitochondrial myopathy (PMM).
U.S. Biotech Firm Stealth May Apply For Hong Kong, S.A.R., China IPO This Year biospectrumasia
May 14, 2018
Hong Kong, S.A.R., China’s exchange last month approved the biggest change to its IPO rules in two decades. It now accepts applications from unprofitable biotech businesses.
US FDA grants fast-track status to Stealth’s elamipretide pharmaceutical-technology
November 30, 2017
The US Food and Drug Administration (FDA) has granted fast-track designation for Stealth BioTherapeutics’ lead candidate, elamipretide, to treat patients with Barth syndrome.